MICHAEL SCHOLL as CEO (chief executive officer) heads the divisions strategy, finance, corporate law, marketing & sales and human resources. After his degree as a business engineer he obtained strategic and organizational business experience working as a business consultant.
Subsequently Michael took up various positions in the development and financing of technology companies.
In this role as Chief Operating Officer (COO) ANDREAS SEIDL is responsible for research & development activities, intellectual property, and quality management. After his studies in chemistry, he obtained his Ph.D. in the area of protein analysis and mass spectrometry at the University of Constance/Germany. Before joining LEUKOCARE AG he held different positions at Hexal AG, Sandoz Biopharmaceuticals and Novartis Technical Research & Development in the area of analytical & pharmaceutical development, analytical characterization, and quality control of biopharmaceuticals.
In the early days of biosimilars he coordinated the pioneering analytical and pharmaceutical development activities of the first wave of biosimilars and contributed to the development and approval of eight biosimilar products and NBEs. A special focus area of his scientific work is the investigation of aggregation and particle formation phenomena and the impact on immunogenicity.